• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Covidien

Covidien

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. Covidien's Wide-Moat Device Business Positioned Well for Long-Term Growth

    R&D investments and a narrowed focus have widened the firm's competitive advantages.

  2. Covidien's Mallinckrodt Spin-Off Faces Challenging Environment

    Mallinckrodt's lack of scale and weak branded business keep it from earning a moat.

  3. The Reluctant Bulls of 2014

    After a few fits and starts, Tyco is now set to trade under three separate tickers starting July 2. Tyco International will retain the TYC ticker, Tyco Electronics will assume the TEL ticker, and Covidien , the health-care concern, will trade as COV . We'll have a separate analyst covering each; ...

  4. Super-Wide Moat in the Making at Medtronic

    The device maker's planned acquisition of Covidien will make it a force to be reckoned with.

  5. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  6. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  7. Ideas From the Wide Moat Focus Index

    Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.

  8. Top 10 Buys and Sells by the Ultimate Stock-Pickers

    A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.

  9. No Surprises in Medtronic's Fiscal Third Quarter

    The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.

  10. Checking Retirement Readiness--and Streamlining Along the Way

    We skinny down the number of holdings for this mid-50s couple who wants to make sure their ample portfolio is on the right track.

12345

©2017 Morningstar Advisor. All right reserved.